Novo Holdings Portfolio Company Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
Deal value up to US$1.05 billion
Novo Holdings co-led Series A financing in Amolyt, supported additional financings and is Amolyt’s largest investor
Acquisition validates Novo Holdings’ strategy to identify and invest long term in high quality European biotech companies
Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announced that its portfolio company Amolyt Pharma (“Amolyt”), has entered into a definitive agreement to be acquired by AstraZeneca at a purchase price of US$800 million upfront and a potential milestone payment of US$250 million.
